Jonas Huhn
Research Subjects
Jonas Huhn has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Oliver Scherf-Clavel
Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany
6 shared publications - Alex M. Dickens
Turku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland
2 shared publications - Anna-Mari Haapanen-Saaristo
Turku Bioscience Centre, University of Turku and Åbo Akademi University 1 , 20520 Turku
2 shared publications - Ilia Evstafev
Turku Bioscience Centre, University of Turku and Åbo Akademi University 1 , 20520 Turku
2 shared publications - Ilkka Paatero
Turku Bioscience Centre, University of Turku and Abo Akademi University
2 shared publications - Jenna Villman
Turku Bioscience Centre, University of Turku and Åbo Akademi University 1 , 20520 Turku
2 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Elsevier in Journal of Lipid Research
A Comprehensive GC-MS Toolbox for Targeted and Untargeted Sterol Analysis
- 27 October 2026
- Published by Elsevier in Journal of Lipid Research
Open AccessA Comprehensive GC-MS Toolbox for Targeted and Untargeted Sterol Analysis
- Open Access
- 1 October 2026
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 19 (10)
Pharmacokinetics and efficacy of tank-water-administered dabrafenib, a BRAF inhibitor, in a zebrafish model of melanoma
Zebrafish models are widely used to study BRAF-mutant melanoma biology. However, long-term treatment of adult fish with small-molecule BRAF inhibitors remains challenging, and pharmacokinetic data to inform rational dosing strategies are largely lacking for most small molecules in zebrafish. Here, we assessed the pharmacokinetics, metabolism and efficacy of continuously tank-water-administered dabrafenib, a BRAF inhibitor, in adult zebrafish. Dabrafenib was rapidly absorbed from tank water, reaching efficacious plasma levels within 1 h, but also showed fast elimination kinetics with a half-life of 1.0 h. Most human metabolites of dabrafenib were detected in zebrafish, suggesting conserved metabolic processes. Continuous tank-water administration achieved therapeutically relevant steady-state dabrafenib plasma levels that inhibited BRAF-driven signaling and produced robust efficacy in vivo in a genetic zebrafish model of BRAF-mutant melanoma without apparent toxicity. Together, these results demonstrate that continuous tank-water administration of dabrafenib is a feasible, efficient and well-tolerated dosing strategy in zebrafish melanoma models, and may facilitate dosing of other small-molecule inhibitors, especially those with a short in vivo half-life in zebrafish.
- 1 October 2026
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 19 (10)
Open AccessPharmacokinetics and efficacy of tank-water-administered dabrafenib, a BRAF inhibitor, in a zebrafish model of melanoma
Zebrafish models are widely used to study BRAF-mutant melanoma biology. However, long-term treatment of adult fish with small-molecule BRAF inhibitors remains challenging, and pharmacokinetic data to inform rational dosing strategies are largely lacking for most small molecules in zebrafish. Here, we assessed the pharmacokinetics, metabolism and efficacy of continuously tank-water-administered dabrafenib, a BRAF inhibitor, in adult zebrafish. Dabrafenib was rapidly absorbed from tank water, reaching efficacious plasma levels within 1 h, but also showed fast elimination kinetics with a half-life of 1.0 h. Most human metabolites of dabrafenib were detected in zebrafish, suggesting conserved metabolic processes. Continuous tank-water administration achieved therapeutically relevant steady-state dabrafenib plasma levels that inhibited BRAF-driven signaling and produced robust efficacy in vivo in a genetic zebrafish model of BRAF-mutant melanoma without apparent toxicity. Together, these results demonstrate that continuous tank-water administration of dabrafenib is a feasible, efficient and well-tolerated dosing strategy in zebrafish melanoma models, and may facilitate dosing of other small-molecule inhibitors, especially those with a short in vivo half-life in zebrafish.
- Open Access
- 29 July 2026
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 281
A fast method for the quantification of bortezomib in serum and rat nervous tissue by liquid chromatography tandem mass spectrometry
- 29 July 2026
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 281
Open AccessA fast method for the quantification of bortezomib in serum and rat nervous tissue by liquid chromatography tandem mass spectrometry
- 7 May 2026
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 48 (5) , 572-597
A Review of Blood-Based Microsampling Devices for Patient-Centered Application in Therapeutic Drug Monitoring
Background: Microsampling devices simplify the collection, transport, and storage of biological samples, thereby playing an important role in therapeutic drug monitoring (TDM). This review summarizes the current developments in blood-based microsampling devices, with a particular focus on their applicability in patient-centered settings. Methods: PubMed was searched for studies on blood-based microsampling devices and their suitability for patient-centered applications. Results: Dried blood spot sampling, the foundational technique for collecting small blood volumes, is limited by hematocrit-dependent variability. New volumetric technologies, such as Mitra volumetric absorptive microsampling, HemaPEN, HemaXis DB10, and Tasso-M20, address this issue and improve patient usability, enabling reliable self-sampling for TDM. Recent plasma separation cards, such as the Telimmune system, have further expanded plasma collection, enabling accurate bedside sampling of defined plasma volumes. This advancement holds significant promise for patient-centered applications because it eliminates the need for conversion between blood and plasma concentrations. Conclusions: Microsampling devices using capillary or volumetric technologies offer promising solutions for patient-centered TDM by enabling accurate and user-friendly home sampling. Among these, HemaXis DB10 and Tasso-M20 improved sampling consistency and ease of use, although clinical validation remains limited. Telimmune plasma separation cards enable direct plasma collection without centrifugation and eliminate the need for blood-to-plasma conversion, despite the limitations of small sample volumes. Overall, current developments demonstrate substantial potential for patient-centered TDM; however, further studies are required to evaluate device-specific suitability across different drugs and patient populations.
- 7 May 2026
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 48 (5) , 572-597
A Review of Blood-Based Microsampling Devices for Patient-Centered Application in Therapeutic Drug Monitoring
Background: Microsampling devices simplify the collection, transport, and storage of biological samples, thereby playing an important role in therapeutic drug monitoring (TDM). This review summarizes the current developments in blood-based microsampling devices, with a particular focus on their applicability in patient-centered settings. Methods: PubMed was searched for studies on blood-based microsampling devices and their suitability for patient-centered applications. Results: Dried blood spot sampling, the foundational technique for collecting small blood volumes, is limited by hematocrit-dependent variability. New volumetric technologies, such as Mitra volumetric absorptive microsampling, HemaPEN, HemaXis DB10, and Tasso-M20, address this issue and improve patient usability, enabling reliable self-sampling for TDM. Recent plasma separation cards, such as the Telimmune system, have further expanded plasma collection, enabling accurate bedside sampling of defined plasma volumes. This advancement holds significant promise for patient-centered applications because it eliminates the need for conversion between blood and plasma concentrations. Conclusions: Microsampling devices using capillary or volumetric technologies offer promising solutions for patient-centered TDM by enabling accurate and user-friendly home sampling. Among these, HemaXis DB10 and Tasso-M20 improved sampling consistency and ease of use, although clinical validation remains limited. Telimmune plasma separation cards enable direct plasma collection without centrifugation and eliminate the need for blood-to-plasma conversion, despite the limitations of small sample volumes. Overall, current developments demonstrate substantial potential for patient-centered TDM; however, further studies are required to evaluate device-specific suitability across different drugs and patient populations.
- Open Access
- 29 April 2026
- Published by Elsevier in SSRN Electronic Journal
Bovine Serum Albumin-Mediated Effects on Colonic Solubility, Mucus Permeation, and Absorption of Celecoxib
Celecoxib was used as a model compound in fasted state simulated colonic fluid (FaSSCoF) to investigate equilibrium drug solubility (Seq), protein binding using rapid equilibrium dialysis (RED), flux and permeability (Papp) across porcine colonic mucus (PCM), and in vivo colonic absorption using a rat intracolonic instillation model. The primary focus was on the role of bovine serum albumin (BSA) as a solubilizing and binding constituent, while bile salts (sodium taurodeoxycholate, TDC) with lecithin and poloxamer 407 were included as comparative systems to evaluate how differences in solubilizer type influence celecoxib permeability and absorption. BSA demonstrated a pronounced solubilizing effect on celecoxib with a 1:1 molar binding ratio, increasing the apparent Seq from 5.1 µg/mL to 92 µg/mL in FaSSCoF containing 15 mg/mL BSA. Under these conditions, diffusion across PCM increased approximately seven-fold compared with FaSSCoF without BSA, accompanied by a four-fold increase in colonic absorption in vivo. In contrast, when celecoxib concentration was maintained constant and BSA was subsequently added to FaSSCoF, diffusion across PCM decreased up to ten-fold at BSA concentrations of 1.5 mg/mL, accompanied by an approximately 30% decrease in colonic absorption in vivo. This behavior is consistent with an increased BSA-bound fraction and a reduced free drug concentration available for transport. The addition of TDC with lecithin or poloxamer 407 similarly increased celecoxib diffusion across PCM and colonic absorption when celecoxib was dissolved at Seq in FaSSCoF, although no statistically significant differences were observed between the solubilizing systems. Overall, these findings demonstrate that solubilizing constituents in colonic fluids can substantially increase drug solubility, mucus permeation, and colonic absorption, highlighting the importance of accounting for protein–drug interactions when evaluating drug behavior in the colon.
- 29 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBovine Serum Albumin-Mediated Effects on Colonic Solubility, Mucus Permeation, and Absorption of Celecoxib
Celecoxib was used as a model compound in fasted state simulated colonic fluid (FaSSCoF) to investigate equilibrium drug solubility (Seq), protein binding using rapid equilibrium dialysis (RED), flux and permeability (Papp) across porcine colonic mucus (PCM), and in vivo colonic absorption using a rat intracolonic instillation model. The primary focus was on the role of bovine serum albumin (BSA) as a solubilizing and binding constituent, while bile salts (sodium taurodeoxycholate, TDC) with lecithin and poloxamer 407 were included as comparative systems to evaluate how differences in solubilizer type influence celecoxib permeability and absorption. BSA demonstrated a pronounced solubilizing effect on celecoxib with a 1:1 molar binding ratio, increasing the apparent Seq from 5.1 µg/mL to 92 µg/mL in FaSSCoF containing 15 mg/mL BSA. Under these conditions, diffusion across PCM increased approximately seven-fold compared with FaSSCoF without BSA, accompanied by a four-fold increase in colonic absorption in vivo. In contrast, when celecoxib concentration was maintained constant and BSA was subsequently added to FaSSCoF, diffusion across PCM decreased up to ten-fold at BSA concentrations of 1.5 mg/mL, accompanied by an approximately 30% decrease in colonic absorption in vivo. This behavior is consistent with an increased BSA-bound fraction and a reduced free drug concentration available for transport. The addition of TDC with lecithin or poloxamer 407 similarly increased celecoxib diffusion across PCM and colonic absorption when celecoxib was dissolved at Seq in FaSSCoF, although no statistically significant differences were observed between the solubilizing systems. Overall, these findings demonstrate that solubilizing constituents in colonic fluids can substantially increase drug solubility, mucus permeation, and colonic absorption, highlighting the importance of accounting for protein–drug interactions when evaluating drug behavior in the colon.
- Open Access
Pharmacokinetics and efficacy of tank-water administered BRAF-inhibitor dabrafenib in a zebrafish model of BRAF-mutant melanoma
Zebrafish models are widely used to study the biology of BRAF-mutant melanoma. However, long-term treatment of adult fish with small molecule BRAF inhibitors is challenging, limiting the usefulness of this model to study treatment-induced effects in melanoma biology. In addition, pharmacokinetic studies on small molecule inhibitors in zebrafish that could inform rational dosing strategies, are largely lacking. Here, we have assessed the pharmacokinetics, metabolism and efficacy of continuous tank water -administered BRAF-inhibitor dabrafenib in adult zebrafish. Our results demonstrate that dabrafenib is quickly absorbed from the tank water, reaching efficacious plasma levels within one hour following treatment, but also shows fast elimination kinetics with a half-life of 1.6 hours. We could detect most of the human metabolites of dabrafenib in zebrafish, suggesting that dabrafenib metabolism in zebrafish follows a similar process as in humans. Continuous tank water -administered dabrafenib led to therapeutically relevant steady-state plasma levels that inhibited the BRAF-driven signaling and growth in zebrafish melanoma cells in vitro , and resulted in robust in vivo efficacy in a genetic zebrafish model of BRAF-mutant melanoma, with no apparent toxicity. Together, our results demonstrate that continuous tank water -administered dabrafenib provides a feasible, efficient, and well-tolerated dosing strategy to study treatment-related effects in zebrafish models of BRAF-mutant melanoma. We expect that tank water-administration may also facilitate the dosing of other small molecule inhibitors, especially those with short in vivo half-life in zebrafish. Highlights: Pharmacokinetic analysis demonstrates fast absorption kinetics and short plasma half-life for tank water -administered dabrafenib in zebrafish Dabrafenib is metabolized in zebrafish following a similar metabolic process as in humans Tank water -administered dabrafenib provides a feasible, efficient, and well-tolerated dosing strategy to study treatment-related effects in zebrafish models of BRAF-mutant melanoma Tank water-administration may facilitate dosing of small molecule inhibitors with short in vivo half-life in zebrafish
Open AccessPharmacokinetics and efficacy of tank-water administered BRAF-inhibitor dabrafenib in a zebrafish model of BRAF-mutant melanoma
Zebrafish models are widely used to study the biology of BRAF-mutant melanoma. However, long-term treatment of adult fish with small molecule BRAF inhibitors is challenging, limiting the usefulness of this model to study treatment-induced effects in melanoma biology. In addition, pharmacokinetic studies on small molecule inhibitors in zebrafish that could inform rational dosing strategies, are largely lacking. Here, we have assessed the pharmacokinetics, metabolism and efficacy of continuous tank water -administered BRAF-inhibitor dabrafenib in adult zebrafish. Our results demonstrate that dabrafenib is quickly absorbed from the tank water, reaching efficacious plasma levels within one hour following treatment, but also shows fast elimination kinetics with a half-life of 1.6 hours. We could detect most of the human metabolites of dabrafenib in zebrafish, suggesting that dabrafenib metabolism in zebrafish follows a similar process as in humans. Continuous tank water -administered dabrafenib led to therapeutically relevant steady-state plasma levels that inhibited the BRAF-driven signaling and growth in zebrafish melanoma cells in vitro , and resulted in robust in vivo efficacy in a genetic zebrafish model of BRAF-mutant melanoma, with no apparent toxicity. Together, our results demonstrate that continuous tank water -administered dabrafenib provides a feasible, efficient, and well-tolerated dosing strategy to study treatment-related effects in zebrafish models of BRAF-mutant melanoma. We expect that tank water-administration may also facilitate the dosing of other small molecule inhibitors, especially those with short in vivo half-life in zebrafish. Highlights: Pharmacokinetic analysis demonstrates fast absorption kinetics and short plasma half-life for tank water -administered dabrafenib in zebrafish Dabrafenib is metabolized in zebrafish following a similar metabolic process as in humans Tank water -administered dabrafenib provides a feasible, efficient, and well-tolerated dosing strategy to study treatment-related effects in zebrafish models of BRAF-mutant melanoma Tank water-administration may facilitate dosing of small molecule inhibitors with short in vivo half-life in zebrafish